T2S Group Holding has made headlines by securing the green light from Morocco's capital markets regulator to proceed with its initial public offering (IPO) on the Casablanca Stock Exchange. This significant move marks the opening of the 2026 IPO market in Morocco with a deal poised to reach up to 1.1 billion dirhams, equivalent to approximately $110 million. The offering is strategically designed to include a capital increase of nearly 350 million dirhams alongside the sale of existing shares valued at around 750 million dirhams. Investors have been given a subscription window from July 13 to July 17, with trading anticipated to commence on July 27 under the ticker symbol T2S. The company aims to offer 4.93 million shares at the price of 223 dirhams each, which places the overall valuation of the business at around 4.86 billion dirhams.
Established in 1992, T2S specializes in providing a wide range of medical equipment, diagnostic systems, radiopharmaceutical products, and hospital software. The group operates through four subsidiaries, employing over 400 individuals, and collaborates with more than 40 international medical technology firms, including prominent names like GE Healthcare. T2S has built a strong presence across more than 20 African nations, showcasing its expansive operational footprint.
In terms of financial performance, T2S reported a revenue of 1.76 billion dirhams and a net profit of 211 million dirhams for the year 2025. The company has ambitious growth projections, expecting revenues to soar to 4.17 billion dirhams by 2030, with net profits anticipated to rise to 607 million dirhams. Key expansion initiatives include launching new oncology projects in Côte d'Ivoire, Mali, and Senegal, in addition to reinforcing its diagnostics and after-sales services.
The proceeds from the IPO are earmarked for several critical developments, including the establishment of a second cyclotron facility in Fez, the deployment of advanced diagnostic equipment, improvements to IT systems, and investments in cybersecurity. Following the IPO, the free float of shares is expected to represent approximately 22.6% of the company, while the existing controlling shareholders will adhere to lock-up agreements to maintain stability in the share price.
This IPO represents a significant milestone in the recovery of Morocco's equity market, which has shown a robust resurgence in public listings following a strong performance in 2025. T2S's operational focus on healthcare technology is particularly timely, given the increasing demand for medical equipment, diagnostics, and cancer treatment across Africa as governments and private entities work to enhance healthcare delivery. Unlike many competitors, T2S distinguishes itself by integrating equipment sales with maintenance services, digital hospital systems, and radiopharmaceutical production, thereby creating diverse revenue streams. Furthermore, this IPO underscores the growing investor appetite for companies with regional expansion strategies, rather than those constrained to the Moroccan market. The planned projects across Côte d'Ivoire, Mali, and Senegal illustrate the vast investment potential in healthcare infrastructure throughout West Africa.
For investors, the pivotal question will be whether T2S can achieve its ambitious growth targets while safeguarding profit margins as it ventures into new markets and increases capital expenditures. The success of this IPO is poised to reaffirm Casablanca's status as one of Africa's most dynamic stock exchanges for new listings. Following the remarkable investor interest seen in companies like SGTM, Vicenne, and Cash Plus in 2025, T2S's offering will be a critical test of whether this momentum can continue into 2026, paving the way for a broader pipeline of large private firms seeking public funding.
As reported by allafrica.com.
